Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Boston Scientific BSX in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 5 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 2 | 4 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Boston Scientific, revealing an average target of $64.9, a high estimate of $71.00, and a low estimate of $61.00. Marking an increase of 7.97%, the current average surpasses the previous average price target of $60.11.
Deciphering Analyst Ratings: An In-Depth Analysis
An in-depth analysis of recent analyst actions unveils how financial experts perceive Boston Scientific. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mike Matson | Needham | Raises | Buy | $71.00 | $60.00 |
| Shagun Singh | RBC Capital | Maintains | Outperform | $67.00 | - |
| Jayson Bedford | Raymond James | Raises | Strong Buy | $67.00 | $61.00 |
| Marie Thibault | BTIG | Maintains | Buy | $64.00 | $64.00 |
| Larry Biegelsen | Wells Fargo | Maintains | Overweight | $62.00 | $62.00 |
| Richard Newitter | Truist Securities | Raises | Buy | $66.00 | $59.00 |
| Larry Biegelsen | Wells Fargo | Raises | Overweight | $62.00 | $59.00 |
| Joshua Jennings | TD Cowen | Raises | Outperform | $65.00 | $58.00 |
| Patrick Wood | Morgan Stanley | Raises | Overweight | $61.00 | $58.00 |
| William Plovanic | Canaccord Genuity | Raises | Buy | $64.00 | $60.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Boston Scientific. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Boston Scientific compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Boston Scientific's stock. This analysis reveals shifts in analysts' expectations over time.
Capture valuable insights into Boston Scientific's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Boston Scientific analyst ratings.
All You Need to Know About Boston Scientific
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Key Indicators: Boston Scientific's Financial Health
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Boston Scientific's remarkable performance in 3 months is evident. As of 30 September, 2023, the company achieved an impressive revenue growth rate of 11.26%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Boston Scientific's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 14.32%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Boston Scientific's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.72%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Boston Scientific's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.49%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Boston Scientific's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.49.
What Are Analyst Ratings?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
